Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DNLINASDAQ:EWTXNASDAQ:OPTNASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNLIDenali Therapeutics$12.03-6.0%$18.27$11.35▼$33.33$1.73B1.581.06 million shs747,300 shsEWTXEdgewise Therapeutics$11.93-12.2%$25.54$11.77▼$38.12$1.14B0.221.07 million shs2.34 million shsOPTOpthea$3.41$4.33$1.79▼$6.30$524.84M1.1226,058 shsN/ATARSTarsus Pharmaceuticals$47.58-4.0%$49.22$20.08▼$57.28$1.81B1.05677,605 shs316,596 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNLIDenali Therapeutics-6.91%-9.93%-19.81%-39.84%-33.97%EWTXEdgewise Therapeutics-12.50%-42.06%-44.57%-51.01%-26.59%OPTOpthea0.00%0.00%-3.94%-9.31%-13.67%TARSTarsus Pharmaceuticals-3.77%-2.17%+11.35%-10.99%+38.10%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDNLIDenali Therapeutics4.2325 of 5 stars4.51.00.04.72.52.50.0EWTXEdgewise Therapeutics1.8921 of 5 stars3.41.00.00.02.92.50.0OPTOpthea0.8475 of 5 stars2.11.00.00.02.20.80.6TARSTarsus Pharmaceuticals2.7396 of 5 stars4.50.00.00.02.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNLIDenali Therapeutics 2.94Moderate Buy$37.20209.36% UpsideEWTXEdgewise Therapeutics 2.75Moderate Buy$40.38238.57% UpsideOPTOpthea 2.17Hold$1.33-60.90% DownsideTARSTarsus Pharmaceuticals 3.00Buy$63.6733.82% UpsideCurrent Analyst Ratings BreakdownLatest OPT, EWTX, DNLI, and TARS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2025EWTXEdgewise TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$56.00 ➝ $52.004/2/2025EWTXEdgewise TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$51.00 ➝ $51.004/2/2025EWTXEdgewise TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSector Outperform ➝ Sector Perform$50.00 ➝ $14.003/25/2025OPTOptheaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$12.00 ➝ $2.003/25/2025OPTOptheaLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$12.00 ➝ $1.003/25/2025OPTOptheaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$8.00 ➝ $1.003/24/2025OPTOptheaLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/24/2025OPTOptheaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/10/2025DNLIDenali TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $28.003/7/2025DNLIDenali TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$41.00 ➝ $33.003/7/2025EWTXEdgewise TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$50.00(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNLIDenali Therapeutics$330.53M5.28N/AN/A$7.42 per share1.62EWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.53 per shareN/AOPTOpthea$87.67K5,986.77N/AN/A($0.56) per share-6.09TARSTarsus Pharmaceuticals$182.95M9.98N/AN/A$5.95 per share8.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNLIDenali Therapeutics-$145.22M-$2.57N/AN/AN/AN/A-32.94%-30.04%5/6/2025 (Estimated)EWTXEdgewise Therapeutics-$100.16M-$1.45N/AN/AN/AN/A-26.83%-25.67%5/8/2025 (Estimated)OPTOpthea-$220.24MN/A0.00N/AN/AN/AN/AN/AN/ATARSTarsus Pharmaceuticals-$135.89M-$3.10N/AN/AN/A-103.64%-55.86%-39.28%5/6/2025 (Estimated)Latest OPT, EWTX, DNLI, and TARS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/3/2025Q4 2024EWTXEdgewise Therapeutics-$0.39-$0.42-$0.03-$0.42N/AN/A2/27/2025Q4 2024DNLIDenali Therapeutics-$0.75-$0.67+$0.08-$0.67$12.75 millionN/A2/25/2025Q4 2024TARSTarsus Pharmaceuticals-$0.68-$0.60+$0.08-$0.60$58.80 million$66.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDNLIDenali TherapeuticsN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/AOPTOptheaN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNLIDenali TherapeuticsN/A9.989.98EWTXEdgewise TherapeuticsN/A26.3526.35OPTOptheaN/A2.942.94TARSTarsus Pharmaceuticals0.305.425.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNLIDenali Therapeutics92.92%EWTXEdgewise TherapeuticsN/AOPTOpthea55.95%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipDNLIDenali Therapeutics7.90%EWTXEdgewise Therapeutics24.11%OPTOpthea3.20%TARSTarsus Pharmaceuticals8.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNLIDenali Therapeutics430145.22 million132.55 millionOptionableEWTXEdgewise Therapeutics6095.21 million71.86 millionOptionableOPTOpthea8153.91 million148.98 millionNot OptionableTARSTarsus Pharmaceuticals5038.38 million35.07 millionOptionableOPT, EWTX, DNLI, and TARS HeadlinesRecent News About These CompaniesBlair William & Co. IL Makes New $1.51 Million Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 4 at 3:47 AM | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of "Buy" by BrokeragesApril 4 at 2:36 AM | marketbeat.comAIGH Capital Management LLC Grows Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)March 31, 2025 | marketbeat.comPrudential Financial Inc. Boosts Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)March 31, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Artisan Partners Limited PartnershipMarch 30, 2025 | marketbeat.comFastest-Growing Public Cos. Ride Healthcare BoomMarch 28, 2025 | ocbj.comTarsus Raises $134.8M Public OfferingMarch 28, 2025 | ocbj.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Bobak R. Azamian Sells 6,000 SharesMarch 27, 2025 | marketbeat.comInsider Selling: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Sells 6,000 Shares of StockMarch 27, 2025 | insidertrades.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Opthea Limited Sponsored ADR (OPT) and Larimar Therapeutics (LRMR)March 25, 2025 | markets.businessinsider.comTarsus Pharmaceuticals (NASDAQ:TARS) Shares Down 2.9% - Time to Sell?March 25, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Insider Sells $107,085.07 in StockMarch 21, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Insider Dianne C. Whitfield Sells 2,315 SharesMarch 21, 2025 | marketbeat.comBryan Wahl Sells 3,084 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) StockMarch 21, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Sells $154,654.89 in StockMarch 21, 2025 | marketbeat.comBobak R. Azamian Sells 7,131 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) StockMarch 21, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Bobak R. Azamian Sells 8,534 SharesMarch 21, 2025 | marketbeat.comDianne C. Whitfield Sells 2,137 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) StockMarch 21, 2025 | insidertrades.comTarsus Pharmaceuticals 2.809M share Spot Secondary priced at $44.50March 13, 2025 | markets.businessinsider.comTarsus prices $125M stock offeringMarch 13, 2025 | msn.comTarsus Announces $100M Public OfferingMarch 12, 2025 | ocbj.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIntel Stock Surges on New CEO – The Real Story Runs DeeperBy Gabriel Osorio-Mazilli | March 13, 2025View Intel Stock Surges on New CEO – The Real Story Runs DeeperSuper Micro Stock: $7.2M Call Options Signal Big Upside PotentialBy Gabriel Osorio-Mazilli | March 24, 2025View Super Micro Stock: $7.2M Call Options Signal Big Upside Potential3 Stocks to Buy While Others Stay on the SidelinesBy Chris Markoch | March 8, 2025View 3 Stocks to Buy While Others Stay on the SidelinesModerna: 4 Key Reasons the CEO Just Bought $5M in SharesBy Jea Yu | March 11, 2025View Moderna: 4 Key Reasons the CEO Just Bought $5M in SharesIntel's Strategy to Win the Next AI FrontierBy Jeffrey Neal Johnson | March 27, 2025View Intel's Strategy to Win the Next AI FrontierOPT, EWTX, DNLI, and TARS Company DescriptionsDenali Therapeutics NASDAQ:DNLI$12.02 -0.77 (-5.98%) As of 01:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Edgewise Therapeutics NASDAQ:EWTX$11.92 -1.66 (-12.19%) As of 01:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Opthea NASDAQ:OPT$3.41 0.00 (0.00%) As of 04/3/2025Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Tarsus Pharmaceuticals NASDAQ:TARS$47.58 -1.97 (-3.98%) As of 01:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Arm Holdings Aims for 50% Data Center Market Share Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Celsius Heats Up: Acquisition, Analyst Upgrade Fuel Momentum Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
